DK0838221T3 - Lyofiliserede HGF-præparater - Google Patents

Lyofiliserede HGF-præparater

Info

Publication number
DK0838221T3
DK0838221T3 DK96922266T DK96922266T DK0838221T3 DK 0838221 T3 DK0838221 T3 DK 0838221T3 DK 96922266 T DK96922266 T DK 96922266T DK 96922266 T DK96922266 T DK 96922266T DK 0838221 T3 DK0838221 T3 DK 0838221T3
Authority
DK
Denmark
Prior art keywords
lyophilized
hgf
hgfs
lyophilizing
stabilizer
Prior art date
Application number
DK96922266T
Other languages
Danish (da)
English (en)
Inventor
Katsumi Tanaka
Kanji Higashio
Eitaro Kumazawa
Original Assignee
Nakamura Toshikazu
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nakamura Toshikazu, Daiichi Seiyaku Co filed Critical Nakamura Toshikazu
Application granted granted Critical
Publication of DK0838221T3 publication Critical patent/DK0838221T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK96922266T 1995-07-11 1996-07-08 Lyofiliserede HGF-præparater DK0838221T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19901895A JP3927248B2 (ja) 1995-07-11 1995-07-11 Ｈｇｆ凍結乾燥製剤
PCT/JP1996/001898 WO1997002832A1 (fr) 1995-07-11 1996-07-08 Preparations lyophilisees de hgf

Publications (1)

Publication Number Publication Date
DK0838221T3 true DK0838221T3 (da) 2007-12-03

Family

ID=16400759

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96922266T DK0838221T3 (da) 1995-07-11 1996-07-08 Lyofiliserede HGF-præparater

Country Status (11)

Country Link
US (3) US20010051604A1 (fr)
EP (1) EP0838221B1 (fr)
JP (1) JP3927248B2 (fr)
KR (2) KR100707713B1 (fr)
AT (1) ATE355850T1 (fr)
AU (1) AU6319896A (fr)
CA (1) CA2226548C (fr)
DE (1) DE69636953T2 (fr)
DK (1) DK0838221T3 (fr)
ES (1) ES2279522T3 (fr)
WO (1) WO1997002832A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634663C (fr) * 1999-02-22 2009-08-25 University Of Connecticut Nouvelles formulations de facteur viii sans albumine
ATE359809T1 (de) * 1999-05-31 2007-05-15 Mitsubishi Chem Corp Gefriergetrocknete hgf-präparationen
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
RU2292216C2 (ru) * 2000-10-31 2007-01-27 Фарма Мар, С.А. Кахалалид f
HUP0600031A3 (en) * 2000-10-31 2012-02-28 Pharma Mar Kahalalide formulations and their use
JP3523188B2 (ja) * 2000-12-13 2004-04-26 富士写真フイルム株式会社 プローブ分子が固定された検出具の水性処理液
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
SE0402433D0 (sv) * 2004-10-08 2004-10-08 Damavand Wound Ab New composition and method
CN100464735C (zh) * 2006-08-02 2009-03-04 沈阳斯佳科技发展有限公司 促肝细胞生长素水针制剂的制备方法
JP5265514B2 (ja) * 2007-02-22 2013-08-14 クリングルファーマ株式会社 Ｈｇｆ製剤
WO2008102452A1 (fr) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Préparation de hgf
KR101290322B1 (ko) 2008-04-09 2013-07-26 주식회사 바이로메드 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제
EP2385825B1 (fr) 2008-11-07 2018-10-10 University of Connecticut Formulation de facteur viii
US9811782B1 (en) * 2010-08-27 2017-11-07 Tri State Distribution, Inc. Method of self-contained recycling of pharmaceutical containers
JP6240337B2 (ja) 2013-10-22 2017-11-29 バイロメッド カンパニー リミテッド 肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
CA2947396C (fr) 2014-04-28 2021-10-19 Eisai R&D Management Co., Ltd. Preparation de hgf lyophilisee
WO2016039163A1 (fr) * 2014-09-10 2016-03-17 クリングルファーマ株式会社 Préparation à base de hgf utilisable pour le traitement de maladies du système nerveux
RU2747977C2 (ru) 2016-03-17 2021-05-18 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ получения активного фактора роста гепатоцитов (hgf)
EP3443346B1 (fr) * 2016-04-13 2023-08-30 Medimmune, LLC Utilisation d'acides aminés en tant que composés stabilisants dans des compositions pharmaceutiques contenant des concentrations élevées d'agents thérapeutiques à base de protéines
EP3468610A1 (fr) 2016-06-09 2019-04-17 OPKO Biologics Ltd. Formulation d'oxyntomoduline à action prolongée, et procédés de production et procédés d'administration de cette dernière
AU2019305221B2 (en) 2018-07-19 2024-11-07 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked DNA gene therapy
IL308496A (en) 2021-05-14 2024-01-01 Claris Biotherapeutics Inc Growth factor compounds for the treatment of eye diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JPH0640937A (ja) * 1990-08-20 1994-02-15 Chiba Seifun Kk Ｌｐｓを含む鎮痛剤及び動物用鎮痛剤
US5234908A (en) * 1991-04-12 1993-08-10 Creative Biomolecules, Inc. Method of treating gastrointestinal ulcers with platelet derived growth factor
TW318142B (fr) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
JP3380573B2 (ja) * 1992-07-16 2003-02-24 第一製薬株式会社 Ｔｃｆ−ｉｉを有効成分とする蛋白合成促進剤
JP3697460B2 (ja) * 1992-07-17 2005-09-21 敏一 中村 Ｈｇｆ含有製剤
JP3622015B2 (ja) * 1992-10-08 2005-02-23 敏一 中村 肺傷害治療剤
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
JP3680114B2 (ja) * 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
JP3818322B2 (ja) * 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤

Also Published As

Publication number Publication date
DE69636953D1 (de) 2007-04-19
JP3927248B2 (ja) 2007-06-06
EP0838221A1 (fr) 1998-04-29
KR19990028819A (ko) 1999-04-15
CA2226548A1 (fr) 1997-01-30
JPH0925241A (ja) 1997-01-28
AU6319896A (en) 1997-02-10
DE69636953T2 (de) 2007-12-06
EP0838221A4 (fr) 2003-01-15
US20030069183A1 (en) 2003-04-10
US20060229245A1 (en) 2006-10-12
US20010051604A1 (en) 2001-12-13
WO1997002832A1 (fr) 1997-01-30
KR100705997B1 (ko) 2007-07-09
ATE355850T1 (de) 2007-03-15
ES2279522T3 (es) 2007-08-16
CA2226548C (fr) 2009-06-02
KR20050096989A (ko) 2005-10-06
US7173008B2 (en) 2007-02-06
KR100707713B1 (ko) 2007-04-16
EP0838221B1 (fr) 2007-03-07

Similar Documents

Publication Publication Date Title
ATE355850T1 (de) Lyophilisierte hgf-zubereitungen
BR9509313A (pt) Formulações de soluções aquosas estáveis de interferon alfa
FI925615A0 (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en hmg-coa-reduktas-inhibitorfoerening
LU91342I2 (fr) Byetta-exénatide
DE3874493D1 (de) Optischer positionssensor, den faraday-effekt benutzend.
DE3871512D1 (de) Waessrige, radierbare tintenzusammensetzungen.
BR9404552A (pt) Composição aquosa
DE68922204D1 (de) Giessbare Sulfon-Peroxycarbonsäurezusammensetzung.
NL1002111C2 (nl) Stabilisatorcombinatie.
ES2055234T3 (es) Agente con contenido de anticoagulante.
FI912348A0 (fi) Stabiliserad fgf sammansaettning.
KR900011887A (ko) 효소 및 효소 안정화 시스템을 함유하는 액체 세제 조성물
FI911502A7 (fi) Elastomerisk upphaengning.
BR9900114A (pt) Composições de ciclodextrina.
DE69012802D1 (de) Stabilisatorstange.
NO942983L (no) Farmasöytiske sammensetninger
ATE250021T1 (de) Hydroxycyclopentanone
PT917458E (pt) Agentes antitumorais de tioxantenona liofilizada
CY1106882T1 (el) Τροποποιηση βητακυτταρουλινης
IT1253704B (it) Soluzioni terapeutiche stabili per uso iniettabile a base di fruttosio-1,6-difosfato sale di sodio o di calcio o di magnesio
NO893862D0 (no) Sikkerhetsstabilisator for kjoeretoeystyring.
KR970042948U (ko) 스태빌라이저 바의 완충구조
KR960020836U (ko) 차량용 능동 스테빌라이져
ITRM920430A1 (it) Composizioni stabilizzate di hdag.
KR970028653U (ko) 자동차의 스테빌라이져 링크